1. Home
  2. TCRX vs LPSN Comparison

TCRX vs LPSN Comparison

Compare TCRX & LPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TCRX
  • LPSN
  • Stock Information
  • Founded
  • TCRX 2018
  • LPSN 1995
  • Country
  • TCRX United States
  • LPSN United States
  • Employees
  • TCRX N/A
  • LPSN N/A
  • Industry
  • TCRX Biotechnology: Pharmaceutical Preparations
  • LPSN EDP Services
  • Sector
  • TCRX Health Care
  • LPSN Technology
  • Exchange
  • TCRX Nasdaq
  • LPSN Nasdaq
  • Market Cap
  • TCRX 82.1M
  • LPSN 72.8M
  • IPO Year
  • TCRX 2021
  • LPSN 2000
  • Fundamental
  • Price
  • TCRX $1.93
  • LPSN $1.02
  • Analyst Decision
  • TCRX Strong Buy
  • LPSN Hold
  • Analyst Count
  • TCRX 6
  • LPSN 3
  • Target Price
  • TCRX $9.50
  • LPSN $1.20
  • AVG Volume (30 Days)
  • TCRX 572.1K
  • LPSN 1.5M
  • Earning Date
  • TCRX 08-11-2025
  • LPSN 08-04-2025
  • Dividend Yield
  • TCRX N/A
  • LPSN N/A
  • EPS Growth
  • TCRX N/A
  • LPSN N/A
  • EPS
  • TCRX N/A
  • LPSN N/A
  • Revenue
  • TCRX $4,421,000.00
  • LPSN $292,025,000.00
  • Revenue This Year
  • TCRX $159.20
  • LPSN N/A
  • Revenue Next Year
  • TCRX N/A
  • LPSN $0.82
  • P/E Ratio
  • TCRX N/A
  • LPSN N/A
  • Revenue Growth
  • TCRX N/A
  • LPSN N/A
  • 52 Week Low
  • TCRX $1.02
  • LPSN $0.61
  • 52 Week High
  • TCRX $7.44
  • LPSN $2.08
  • Technical
  • Relative Strength Index (RSI)
  • TCRX 63.03
  • LPSN 58.54
  • Support Level
  • TCRX $1.75
  • LPSN $0.93
  • Resistance Level
  • TCRX $1.96
  • LPSN $1.07
  • Average True Range (ATR)
  • TCRX 0.14
  • LPSN 0.08
  • MACD
  • TCRX 0.01
  • LPSN -0.00
  • Stochastic Oscillator
  • TCRX 94.00
  • LPSN 54.17

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

About LPSN LivePerson Inc.

LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.

Share on Social Networks: